CMTM7 and triple-negative breast carcinoma: In addition, CMTM7 expression was remarkably higher in patients with triple-negative breast cancer (TNBC) (p < 0.0001, Figures 1A,I), a molecular subtype with dead aggressiveness and a lack of effective therapies (Mei et al., 2020), but often overexpressing PD-L1 and showing encouraging therapeutic responses to immunotherapy (Mei et al., 2021b; Majidpoor and Mortezaee, 2021).